ArticleRomanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
Immunohistochemical predictors of local recurrence in breast carcinoma: development and sensitivity validation of an IHC-based risk score.
Article in Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLocal recurrence after breast-conserving surgery (BCS) remains clinically relevant and is associated with poorer long-term outcomes. While several prediction tools exist, many rely on costly genomic assays or omit key biological variables routinely assessed by immunohistochemistry (IHC). PATIENTS, MATERIALS AND
methodsWe retrospectively analyzed 100 consecutive patients with invasive breast carcinoma treated by BCS (2013-2018). IHC data included estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2∕neu) [0-3+, with 2+ confirmed by chromogenic in situ hybridization (CISH)], as well as hormonal phenotypes. Local recurrence occurred in 21 cases. An integrated IHC score (0-6 points) was constructed using weighted biological predictors (ER-, PR-, HER2+, and ER-∕PR- phenotype), stratifying cases into low (0-2), moderate (3-4), and high (≥5) risk categories. Although ER, PR, and HER2 status were available for all cases, case-level linkage between HER2 positivity and ER∕PR phenotypes was not consistently available; therefore, three sensitivity scenarios (optimistic, neutral, and pessimistic) were applied to assess the robustness of the findings.
resultsRecurrence was higher in biologically unfavorable subgroups: ER- (26.47% vs. 9.09% in ER+), PR- (21.42% vs. 10.34% in PR+), ER-∕PR- phenotype (37.5%), and HER2-positive tumors (33.33% vs. 11.36% in HER2-). The integrated score achieved consistent separation of risk categories, with most recurrences concentrated in moderate- and high-risk groups. Sensitivity analyses showed stable stratification across all three HER2 allocation scenarios, supporting the robustness of the model despite uncertainty in HER2- phenotype overlap.
conclusionsA pragmatic IHC-based risk score based on routinely available biomarkers stratified local recurrence risk in breast cancer patients treated with BCS and remained stable under sensitivity testing. External validation in larger, multicenter cohorts is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.